secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-10-05T13:00:06+00:00
Accession:  0001193125-26-413254
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

PMV Pharmaceuticals Appoints Matt Eckler to Board; Plans Q1 2027 NDA for Rezatapopt
--------------------------------------------------------------------------------

- Dr. Matthew Eckler was appointed to PMV Pharmaceuticals' board on October 1, 2026, with a term expiring at the 2029 annual meeting.
- Eckler is a Principal at Samsara BioCapital and previously worked at ArrowMark Partners and GMT Capital; he will receive $40,000 annual cash compensation.
- He received an initial stock option award for 84,000 shares and is expected to receive annual options for 42,000 shares under the outside director policy.
- PMV plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation in Q1 2027.
- The PYNNACLE Phase 2 monotherapy portion completed enrollment; rezatapopt has FDA Fast Track and Orphan Drug designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526413254/0001193125-26-413254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526413254/d174662d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-413254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer